At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 391 enrolled
Drug / intervention
Atomoxetine +1 moredrug
Likely dose
Atomoxetine 120 milligramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind Placebo-Controlled Asian Study of Atomoxetine Hydrochloride in the Treatment of Adult Patients With Attention-Deficit/Hyperactivity Disorder (ADHD)
In Brief
A Phase 3 clinical trial evaluating Atomoxetine and Placebo for Attention Deficit Hyperactivity Disorder. Completed, enrolled 391 participants across 24 sites in 3 countries.
Detailed Summary
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder
CountriesJapan, South Korea, Taiwan
Collaborators--
Timeline
Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedAug 2009
Primary CompletionFeb 2011
TodayJul 2026
First PostedAug 19, 2009
Enrollment StartAug 1, 2009
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.9 years ago
Interventions
Atomoxetinedrug
40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
Placebodrug
Taken by mouth, once daily for 10 weeks.